Use of akkermansia in the treatment of oral diseases

a technology of akkermansia and oral cavity, which is applied in the field of oral disease treatment, can solve problems such as tooth loss

Pending Publication Date: 2020-12-24
AMAR SALOMON +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Left untreated, periodontitis may destroy the periodontal ligament and the supporting alveolar bone, eventually leading to tooth loss.
Antibi...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of akkermansia in the treatment of oral diseases
  • Use of akkermansia in the treatment of oral diseases
  • Use of akkermansia in the treatment of oral diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

: A. muciniphila Decreases P. gingivalis-Induced Soft Tissue Inflammation and Calvarial Bone Destruction

Methods

Mouse Calvarial Bone Resorption Model

[0244]Mice were separated into the following four treatment groups (n=6): (i) PBS, (ii) P. gingivalis alone, (iii) A. muciniphila alone and (iv) P. gingivalis and A. muciniphila injected combined. Mice were anesthetized by the intraperitoneal injection of ketamine-xylazine (Akorn Animal Health, Lake Forest, Ill., USA). The heads of mice were shaved and cells of P. gingivalis (5×108), A. muciniphila (109) or no cells in 100 μL of PBS were injected subcutaneously in the 4 treatment groups with a 30.5-gauge needle at a point on the midline of the skull between the ears and eyes as described previously {Huck:2017gj}. Lesions were photographed each day for 5 days. Mice were sacrificed 5 days post injection. The size of the lesion resulting from the injection in each animal (area in square millimeters) was analyzed using ImageJ software.

Histol...

example 2

ic Administration of A. muciniphila Reduced P. gingivalis-Induced Alveolar Bone Destruction

Methods

[0263]Induction of Periodontitis and A. muciniphila Administration

[0264]Sterile black braided 6.0 silk sutures were incubated in bacterial culture medium with P. gingivalis for 1 day in anaerobic conditions. Following anesthesia, P. gingivalis soaked 6.0 ligatures were placed in the sulcus around the maxillary first and second molars as previously described {SaadiThiers:2012by}. Ligatures were replaced 3 times / week during 5 weeks. On days in-between ligature placement, oral gavage with P. gingivalis (5×108 cells) was performed as previously described {Alshammari:2017ip}. After 5 weeks of periodontitis induction, the ligatures were removed and mice were split in two groups (i) with daily oral gavage of P. gingivalis alone (5×108 cells) and (ii) with daily oral gavage of A. muciniphila (109 cells) and with P. gingivalis for an additional 2 weeks.

Morphometric Analysis

[0265]Palatal bone was...

example 3

: A. muciniphila Administration is Associated with a Shift of Periodontal and Gut Microbiota

Materials and Methods

Material

Oral and Fecal Sample Collection and Storage

[0269]Oral samples were collected by gently rubbing a sterile paper point over gums and teeth. Paper points were immediately placed into a sterile tube and stored at −80° C. Fresh fecal samples were collected from mouse into sterile tube and stored at −80° C. until analysis.

Methods

DNA Extraction, Sequencing and Data Processing

[0270]DNA was isolated from oral and fecal samples as described previously {Caporaso:2012fz}. Samples were placed in PowerBead Tubes and vortexed for 10 min at maximum speed using a 24-sample vortex adapter. The samples were processed following the manual and protocols according to the instructions in the DNeasy PowerSoil Kit Handbook (Qiagen, Calif.). The quality and quantity of DNA was determined by fluorometric quantification and by measuring A260 / A280 ratios. In addition, the DNA was visualized ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of Akkermansia and/or fragments thereof in the treatment and/or prevention of oral diseases. In particular, the present invention relates to Akkermansia muciniphila and/or fragments thereof, such as proteins and secreted molecules, for use in treating and/or preventing oral diseases.

Description

FIELD OF INVENTION[0001]The present invention relates to the treatment of oral diseases. More specifically, the present invention relates to the use of Akkermansia spp. and / or fragments thereof for treating oral diseases.SEQUENCE LISTING[0002]An official copy of the sequence listing is submitted concurrently with the specification electronically via EFS-Web as an ASCII formatted sequence listing with a file name of 791-014.006_ST25.TXT, a creation date of Mar. 26, 2020, and a size of about 5.5 kilobytes. The sequence listing contained in this ASCII formatted document is part of the specification and is herein incorporated by reference in its entirety.BACKGROUND OF INVENTION[0003]Several oral diseases, in particular gingivitis and periodontitis, are caused by bacteria in the dental plaque, the biofilm that grows on surfaces within the mouth. The buildup of plaque is associated with the subsequent inflammation of the gum tissues, that, swollen, detach form the tooth and thereby furthe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/74
CPCA61K9/0014A61K9/0053A61K35/74A61K35/741A61Q11/00A61P1/02
Inventor AMAR, SALOMONDEVOS, WILLEM M.
Owner AMAR SALOMON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products